Nei Podcast

What do we know about the world suicide rate and the national suicide rate? What are the differences and how might they be explained? How does the role of medications help or hinder suicide prevention? In this episode, Dr. Andrew Cutler interviews Dr. Christine Moutier and Dr. Stephen Stahl on their Suicide Prevention Handbook, where they address timely questions like these and so much more. Dr. Moutier is the Chief Medical Officer of the American Foundation for Suicide Prevention (AFSP).  Throughout her career she has focused on fighting stigma related to mental health and help seeking. Training healthcare leaders, physicians, and advocacy groups, Dr. Moutier has sought to change the healthcare system’s approach to mental health, in order to optimize care for those suffering from mental health conditions. As a leader in the field of suicide prevention, Dr. Moutier joined AFSP in 2013, and has revitalized AFSP’s Education team, re-launched its Loss & Healing department, and expanded AFSP’s support to incl

What are the positive and negative consequences surrounding self-diagnosis programs for mental health? What can you say about the trend on TikTok to take L-tyrosine? It’s apparently been nicknamed the “natural Adderall”. What is wrong with this, or potentially dangerous about this? In this episode, Dr. Kojo Sarfo, discusses the positive and negative consequences of the mental health trends on TikTok and social media. Dr. Kojo Sarfo, DNP, PMHNP-BC is a Ghanaian-American Psychiatric-Mental Health Nurse Practitioner, entrepreneur, and writer. He graduated from The University of West Alabama with his Associate’s Degree in Nursing and then obtained his Bachelor’s in Nursing from Western Governors University. He went on to obtain his Doctorate in Nursing Practice degree from Augusta University with a specialty in Psychiatry. Dr. Sarfo is dedicated to increasing awareness about mental health conditions and reducing the stigma that surrounds mental health on social media platforms, such as TikTok. His mission has bee

What are the most frequent comorbidities of schizophrenia? Is there any scientific reason to use any antipsychotic in twice-a-day dosing? In this episode, Dr. Leslie Citrome addresses these questions and more of your unanswered questions from the NEI Synapse Half-Day on Novel Strategies to Treat Schizophrenia in this special NEI Podcast Bonus episode! Dr. Leslie Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York and has a private practice in Pomona, New York. He is the Editor-in-Chief of the International Journal of Clinical Practice, published by Wiley. Dr. Citrome was the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, and after nearly two decades of government service as a researcher in the psychopharmacological treatment of severe mental disorders, Dr. Citrome is now engaged as a consultant in clinical trial design and interpretation. Dr.

What unique risk factors surround the COVID-19 pandemic and potential heightened risk of suicide? What populations have been most vulnerable to mental health consequences, substance use disorders, suicidal ideation, and self-harm during the pandemic and why? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on the suicide risk and prevalence during this challenging time. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and

What are some mental health challenges for Asian Americans today? Can you share your thoughts on the most recent acts of violence against Asian Americans and where it comes from? In this timely and important episode, we interview Dr. Rona Hu on mental health in the Asian American community. Dr. Hu is Medical Director of the Acute Psychiatric Inpatient Unit at Stanford Hospital, specializing in the care of those with serious mental illnesses, including schizophrenia, bipolar and depression. She completed medical school and residency in psychiatry at the University of California, San Francisco, and fellowships in Pharmacology and Schizophrenia Research through the National Institutes of Health. She is also active in  minority issues and cultural psychiatry, and has received regional and national recognition for her clinical care, research and teaching. Dr. Rona J. Hu received her medical degree in 1990 from the University of California, San Francisco School of Medicine, and completed her residency at the Unive

What is the evidence that obesity leaves one vulnerable to bipolar disorder? Which of your patients with bipolar disorder would you refer for TMS and what has been the outcome in your experience? Have you seen development of mania with this treatment? What impact or changes have you seen in your bipolar patients who have suffered with COVID? In this Bonus episode of the NEI Podcast, Dr. Roger McIntyre addresses these questions and more unanswered questions from the Q&A session for our NEI Synapse Half-Day on The Cutting-Edge of Mood Disorders. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive

What do clinicians need to know about the pharmacokinetics of ketamine, especially when it comes to drug-drug interactions? What is the abuse potential for ketamine and for esketamine? What are some ways that clinicians can mitigate the risk of abuse? At this time, what is the consensus, in comparing the efficacy of ketamine and esketamine for treatment resistant depression? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on their recent publication in the American Journal of Psychiatry. To access the article click on the link: https://pubmed.ncbi.nlm.nih.gov/33726522/ Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most

What has the research shown in terms of the relationship between THC and sleep and nightmares in patients with PTSD? What are your thoughts on the recent study by LaFrance et al. that claimed that PTSD symptoms were reduced by more than 50% after cannabis use? In this fascinating interview with Dr. Kari Franson, we discuss the evidence for and against the use of cannabis to treat PTSD. Kari L. Franson PharmD, PhD, BCPP joined the University of Southern California in 2020 as the Associate Dean for Academic and Student Affairs and Professor of Clinical Pharmacy. Dr. Franson received her Doctor of Pharmacy from the University of California, San Francisco, trained at the University of Illinois, Chicago Hospital and Clinics as a resident in adult internal medicine and a fellow in clinical research/drug development, and received her PhD in Medical Education from Leiden University, the Netherlands. Dr. Franson is an educator with more than 25 years of experience. Throughout her career, she has focused on two areas:

What exactly is reconsolidation? How does disrupting this process work to neutralize fear conditioning? How has hallucinogen-assisted psychotherapy been implemented as an attempt to block reconsolidation of activated memories during psychotherapy sessions In this episode, as part of our special series, the PsychopharmaStahlogy Show, Dr. Andrew Cutler asks Dr. Stephen Stahl these questions, and so much more! Don’t miss Part 3 of this interview.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include: Part 1: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy Part 2: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process Part 3: Forgetting Your PTSD: Using

What are the risk factors for pediatric anxiety, and how might those be altered by the pandemic? How can emotional intelligence and emotion regulation play a role in managing anxiety? What is self-efficacy, and why is it so important for managing pediatric anxiety? In this timely episode, we discuss how to manage pediatric anxiety with Dr. Krystal Lewis. Dr. Lewis is clinical psychologist with the Section on Development and Affective Neuroscience (SDAN) at the National Institute of Mental Health (NIMH). She is also a member of the Stigma Scientific Interest Group (SIG), and the NIMH Anti-Racism Task Force at the National Institute of Health (NIH). She specializes in cognitive behavioral therapy (CBT) for treating pediatric anxiety, and her research has focused on identifying mechanisms underlying the effectiveness of CBT. Dr. Lewis has extensive clinical experience treating anxious children and adolescents. She is also an advocate for early intervention, prevention and evidence-based treatments. She is curren

What has research shown about the effectiveness of psychedelic or dissociative agents in the treatment of addiction? What is pharmacological extinction? What types of addictions have been researched, using this method as a treatment approach? In Part II of this special series, the PsychopharmaStahlogy Show Dr. Andrew Cutler asks Dr. Stephen Stahl these questions, and so much more! Don’t miss Part III of this interview.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include: Part I: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy Part II: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process Part III: Forgetting Your PTSD: Using Reconsolidation to Fo

What are the greatest mental health disparities in this population? What has been particularly challenging for the transgender population during the COVID-19 pandemic? How can clinicians help recognize and treat the mental health needs of patients in the LGBTQ community, if they do not have advanced or specialized training for this population? In this double-interview we had the opportunity to sit down with two experts who address these questions, and so much more! Dr. Rhonda Schwindt is an Associate Professor and Director of the Psychiatric-Mental Health Nurse Practitioner Program at The George Washington University School of Nursing. She is a nationally certified Psychiatric-Mental Health Nurse Practitioner with an active clinical practice specializing in LBGTQ health, trauma, and treatment-resistant psychiatric illnesses. Dr. Schwindt’s research is focused on reducing the disproportionate impact of substance use disorders among high risk populations. She has developed an innovative online module that prepa

What types of psychotherapies are typically used in conjunction with these dissociative agents? How does psilocybin differ from ketamine for the treatment of mental health conditions? What are the risks, if any associated with this type of therapeutic approach? In Part I of this special series, the PsychopharmaStahlogy Show Dr. Andrew Cutler asks Dr. Stephen Stahl these questions, and so much more! Don’t miss Part II and Part III of this interview.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include: Part I: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy Part II: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process Part III: Forgetting Your PTS

In this excerpt, taken from his  presentation on the mental health consequences of COVID-19 for 2020NEIMax!, Dr. Sauve' addresses the rise in substance use disorders, and domestic violence as a result of the 2020 pandemic.  Dr. William M. Sauvé received his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and completed his residency in adult psychiatry at the National Capitol Consortium in Washington, DC, prior to deploying to the Al Anbar Province, Iraq, as the Regimental Psychiatrist for the 7th Marines. After eleven years of active duty service, Dr. Sauvé left the United States Navy to become the Clinical Director of the Military Program at Poplar Springs Hospital in Petersburg, VA, an inpatient structured program for the treatment of Posttraumatic Stress Disorder and Chemical Dependency that caters exclusively to the military population. In 2014, he left Poplar Springs Hospital to focus on Transcranial Magnetic Stimulation and now serves as the Regional

We know that the COVID-19 pandemic has had a significant impact on mental health around the world. Can you share some findings with us on the effect of COVID-19 on mood disorders from the CLIMB study that was conducted this year? What were some of the new FDA approvals for medications that happened this year? In this episode, Dr, Cutler addresses these questions and so much more, as we take a look back at this year in psychopharmacology. Dr. Andrew J. Cutler is Chief Medical Officer at the Neuroscience Education Institute, and Clinical Professor in the Department of Psychiatry at SUNY Upstate Medical University, Syracuse, NY Dr. Cutler has been Principal Investigator (PI) on over 400 psychiatric and medical clinical trials. He has authored over 50 peer-reviewed scientific articles and has authored and presented over 100 abstracts/posters at various scientific meetings. He serves as a peer reviewer for many prestigious scientific and medical journals and serves or has served on several Editorial Boards. He h

Neurodegenerative disorders have become increasingly prevalent today and can often be accompanied by dementia and other neuropsychiatric conditions such as psychosis. It is important to be able to differentiate psychosis that is associated with various types of dementia, while this can be challenging to clinicians. However, there are several existing and novel therapeutics that can manage dementia-related psychosis. In this episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo on the practical strategies for the management of dementia-related psychosis. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-DemPsychosis Learning Objectives: After completing this educational activity, you should be better able to: Describe the clinical presentation of psychosis in dementia Employ pharmacological treatment strategies to ameliorate psychosis in patients with dementia Accreditation and Credit Designa

Despite increasing evidence that bipolar disorders often emerge in adolescence, only about half of adolescents with a bipolar disorder receive mental health care. Research has shown that an early onset of a bipolar disorder, concomitant with a poor diagnosis and lack of treatment, can have lifelong devastating effects for the patient. Adults and younger people who initially exhibit symptoms only of depression may later develop bipolar disorder. The risk of depression turning into bipolar disorder is estimated at 10 percent or less in adults but appears to be as high as 20–40 percent in children and adolescents. In this episode, Dr. Neera Ghaziuddin answers many questions regarding how to better diagnosis and treat pediatric bipolar disorder, and depression with mixed features in the pediatric population. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-PedBip Learning Objectives: After completi

How can someone tell whether they are experiencing chronic levels of stress? The holidays are typically a great source of stress for most people. What are the unique challenges that we face this year in terms of the holidays during a pandemic? In this timely interview, Dr. Jennifer Love addresses these important questions, and so much more in this episode. With the release of her upcoming book, “When Crisis Strikes” she shares some powerful tips on detecting and managing chronic stress. Dr. Jennifer Love is board-certified in psychiatry, addiction psychiatry and addiction medicine, and is a Diplomate of the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. She practices at a large clinic in Southern California. Dr. Love is an award-winning researcher and international speaker, interested in the interface between cultural and spiritual factors and overall mental health. Dr. Love’s work focuses on restoring life balance, brain and body health, and helping her patients impr

Tardive dyskinesia (TD) is a movement disorder characterized by involuntary movements of the tongue, lips, face, trunk, and extremities that occur in patients treated with dopamine receptor blocking agents (DRBAs). Patients can have symptoms that persist for months, years, or even permanently. Greater awareness about risk factors and which agents may be associated with higher likelihood of developing TD is critical to reduce the prevalence of this disorder. Understanding the most effective novel treatment approaches to TD is also important. In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the current best practices in the diagnosis, recognition, and treatment of tardive dyskinesia.  Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-TD  Learning Objectives: After completing this educational activity, you should be better able to: Identify the clinical presentation of tardiv

What are the most common reasons for insomnia? What is effective for treating insomnia? Can you explain sleep hygiene? In Part 2 she answers these questions and so much more! Dr. Jade Wu is a licensed clinical psychologist, sleep researcher, and host of the Savvy Psychologist podcast. She is a frequent guest on popular radio and podcast shows such as NPR, and quoted in popular press publications like New York Times, NBC News, and Huffington Post. Her current research focuses on treating sleep disorders in those with chronic illness. In the clinic, Dr. Wu uses evidence-based non-medication treatments to help people improve their sleep (and wake). Her approach is grounded in both science and compassion, so that her clients are empowered to live healthier and more fulfilled lives.  My website: www.JadeWuPhD.com Twitter: @JadeWuPhD Resources can be found on her website under the "Resources" tab.